{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:27:43Z","timestamp":1786519663219,"version":"build-2736575974"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006209","name":"Radboud University Medical Center","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite advances in IgG-based cancer immunotherapy, challenges remain in effectively engaging innate immune responses against solid tumors. Here, IgA antibodies hold promise due to their ability to activate neutrophils and macrophages. We present a novel retargeted adenovirus-mediated approach that transforms cancer cells into \u201cbiofactories\u201d for localized production of monomeric or dimeric IgA antibodies and a CD47 blocker to potentiate the effect of IgA antibodies. With our approach, tumor cells effectively produced IgA antibodies against tumor antigens such as EGFR or EpCAM and a soluble SIRP\u03b1-Fc fusion protein, which blocks the CD47-SIRP\u03b1 axis. In a perfused tumor-on-a-chip model, locally produced IgA triggered neutrophil- and macrophage-mediated tumor cell killing, further potentiated by SIRP\u03b1-Fc co-production. In Fc\u03b1RI-transgenic, tumor-bearing mice, intratumoral adenoviral injection induced strong local IgA and SIRP\u03b1-Fc expression, immune cell infiltration, and more than 50% tumor volume reduction after a single treatment. We found that dimeric IgA exerts stronger effects than monomeric IgA. Together, these results demonstrate that adenovirus-mediated, tumor-restricted delivery of IgA antibodies and CD47 blockade effectively engages innate immune mechanisms and has therapeutic promise.<\/jats:p>","DOI":"10.1038\/s44321-026-00477-7","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:41:48Z","timestamp":1783442508000},"page":"3226-3257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy"],"prefix":"10.1038","volume":"18","author":[{"given":"Mariya","family":"Chernyavska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K Patricia","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3760-4308","authenticated-orcid":false,"given":"J H Marco","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Kolibius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3160-5542","authenticated-orcid":false,"given":"Dominik","family":"Br\u00fccher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Kristoforus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rens H W","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Huijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Laarveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9368-5661","authenticated-orcid":false,"given":"Marta","family":"Lustig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2979-1730","authenticated-orcid":false,"given":"Nadine","family":"Gimenez de Assis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette H W","family":"Leusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9181-8067","authenticated-orcid":false,"given":"Thomas","family":"Valerius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4191-5306","authenticated-orcid":false,"given":"Andreas","family":"Pl\u00fcckthun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2463-277X","authenticated-orcid":false,"given":"Wouter P R","family":"Verdurmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"477_CR1","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.4049\/jimmunol.1300261","volume":"192","author":"E Aleyd","year":"2014","unstructured":"Aleyd E, van Hout MW, Ganzevles SH, Hoeben KA, Everts V, Bakema JE, van Egmond M (2014) IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via Fcalpha receptor I. J Immunol 192:2374\u20132383","journal-title":"J Immunol"},{"key":"477_CR2","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/bjc.2017.356","volume":"117","author":"S Aras","year":"2017","unstructured":"Aras S, Zaidi MR (2017) TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer 117:1583\u20131591","journal-title":"Br J Cancer"},{"key":"477_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30384-7","volume":"13","author":"JM Ayuso","year":"2022","unstructured":"Ayuso JM, Virumbrales-Munoz M, Lang JM, Beebe DJ (2022) A role for microfluidic systems in precision medicine. Nat Commun 13:3086","journal-title":"Nat Commun"},{"key":"477_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-0530-4","volume":"18","author":"R Baghban","year":"2020","unstructured":"Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P (2020) Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal 18:59","journal-title":"Cell Commun Signal"},{"key":"477_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.949140","volume":"13","author":"N Baumann","year":"2022","unstructured":"Baumann N, Arndt C, Petersen J, Lustig M, Rosner T, Klausz K, Kellner C, Bultmann M, Bastian L, Vogiatzi F et al (2022) Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab. Front Immunol 13:949140","journal-title":"Front Immunol"},{"key":"477_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbiotec.2021.02.013","volume":"331","author":"V Bhaskara","year":"2021","unstructured":"Bhaskara V, Leal MT, Seigner J, Friedrich T, Kreidl E, Gadermaier E, Tesarz M, Rogalli A, Stangl L, Wallwitz J et al (2021) Efficient production of recombinant secretory IgA against Clostridium difficile toxins in CHO-K1 cells. J Biotechnol 331:1\u201313","journal-title":"J Biotechnol"},{"key":"477_CR7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41586-020-03144-0","volume":"591","author":"S Biswas","year":"2021","unstructured":"Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA, Costich TL, Moran C, Harro CM, Rigolizzo KE et al (2021) IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature 591:464\u2013470","journal-title":"Nature"},{"key":"477_CR8","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/emmm.201201929","volume":"5","author":"P Boross","year":"2013","unstructured":"Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N et al (2013) IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 5:1213\u20131226","journal-title":"EMBO Mol Med"},{"key":"477_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.943","volume":"12","author":"R Bouwstra","year":"2022","unstructured":"Bouwstra R, van Meerten T, Bremer E (2022) CD47-SIRPalpha blocking-based immunotherapy: current and prospective therapeutic strategies. Clin Transl Med 12:e943","journal-title":"Clin Transl Med"},{"key":"477_CR10","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3389\/fimmu.2019.00704","volume":"10","author":"AM Brandsma","year":"2019","unstructured":"Brandsma AM, Bondza S, Evers M, Koutstaal R, Nederend M, Jansen JHM, Rosner T, Valerius T, Leusen JHW, Ten Broeke T (2019) Potent Fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG. Front Immunol 10:704","journal-title":"Front Immunol"},{"key":"477_CR11","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1158\/2326-6066.CIR-15-0099-T","volume":"3","author":"AM Brandsma","year":"2015","unstructured":"Brandsma AM, Ten Broeke T, Nederend M, Meulenbroek LA, van Tetering G, Meyer S, Jansen JH, Beltran Buitrago MA, Nagelkerke SQ, Nemeth I et al (2015) Simultaneous targeting of FcgammaRs and FcalphaRI enhances tumor cell killing. Cancer Immunol Res 3:1316\u20131324","journal-title":"Cancer Immunol Res"},{"key":"477_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fimmu.2019.00553","volume":"10","author":"A Breedveld","year":"2019","unstructured":"Breedveld A, van Egmond M (2019) IgA and FcalphaRI: pathological roles and therapeutic opportunities. Front Immunol 10:553","journal-title":"Front Immunol"},{"key":"477_CR13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.omtm.2021.01.002","volume":"20","author":"D Br\u00fccher","year":"2021","unstructured":"Br\u00fccher D, Kirchhammer N, Smith SN, Schumacher J, Schumacher N, Kolibius J, Freitag PC, Schmid M, Weiss F, Keller C et al (2021) iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy. Mol Ther Methods Clin Dev 20:572\u2013586","journal-title":"Mol Ther Methods Clin Dev"},{"key":"477_CR14","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3390\/cancers13081946","volume":"13","author":"E Cendrowicz","year":"2021","unstructured":"Cendrowicz E, Sas Z, Bremer E, Rygiel TP (2021) The role of macrophages in cancer development and therapy. Cancers 13:1946","journal-title":"Cancers"},{"key":"477_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.932155","volume":"13","author":"C Chan","year":"2022","unstructured":"Chan C, Lustig M, Baumann N, Valerius T, van Tetering G, Leusen JHW (2022) Targeting myeloid checkpoint molecules in combination with antibody therapy: a novel anti-cancer strategy with IgA antibodies? Front Immunol 13:932155","journal-title":"Front Immunol"},{"key":"477_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT et al (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142:699\u2013713","journal-title":"Cell"},{"key":"477_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.635173","volume":"12","author":"S Chen","year":"2021","unstructured":"Chen S, Lai SWT, Brown CE, Feng M (2021) Harnessing and enhancing macrophage phagocytosis for cancer therapy. Front Immunol 12:635173","journal-title":"Front Immunol"},{"key":"477_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-022-00345-3","volume":"11","author":"Y Chen","year":"2022","unstructured":"Chen Y, Hu H, Tan S, Dong Q, Fan X, Wang Y, Zhang H, He J (2022) The role of neutrophil extracellular traps in cancer progression, metastasis and therapy. Exp Hematol Oncol 11:99","journal-title":"Exp Hematol Oncol"},{"key":"477_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ooc.2022.100019","volume":"4","author":"M Chernyavska","year":"2022","unstructured":"Chernyavska M, Hermans CKJC, Chan C, Baumann N, R\u00f6sner T, Leusen JHW, Valerius T, Verdurmen WPR (2022) Evaluation of immunotherapies improving macrophage anti-tumor response using a microfluidic model. Organs-on-a-Chip 4:100019","journal-title":"Organs-on-a-Chip"},{"key":"477_CR20","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1007\/s00262-023-03572-7","volume":"72","author":"M Chernyavska","year":"2023","unstructured":"Chernyavska M, Masoudnia M, Valerius T, Verdurmen WPR (2023) Organ-on-a-chip models for development of cancer immunotherapies. Cancer Immunol Immunother 72:3971\u20133983","journal-title":"Cancer Immunol Immunother"},{"key":"477_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54939-9","volume":"9","author":"M Chernyavska","year":"2019","unstructured":"Chernyavska M, Schmid M, Freitag PC, Palacio-Castaneda V, Piruska A, Huck WTS, Pl\u00fcckthun A, Verdurmen WPR (2019) Unravelling Receptor and RGD Motif Dependence of Retargeted Adenoviral Vectors using Advanced Tumor Model Systems. Sci Rep 9:18568","journal-title":"Sci Rep"},{"key":"477_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/19420862.2015.1008351","volume":"7","author":"J Chng","year":"2015","unstructured":"Chng J, Wang T, Nian R, Lau A, Hoi KM, Ho SC, Gagnon P, Bi X, Yang Y (2015) Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells. MAbs 7:403\u2013412","journal-title":"MAbs"},{"key":"477_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1037033","volume":"14","author":"A Cottignies-Calamarte","year":"2023","unstructured":"Cottignies-Calamarte A, Tudor D, Bomsel M (2023) Antibody Fc-chimerism and effector functions: when IgG takes advantage of IgA. Front Immunol 14:1037033","journal-title":"Front Immunol"},{"key":"477_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semcancer.2021.07.011","volume":"79","author":"L Cristinziano","year":"2022","unstructured":"Cristinziano L, Modestino L, Antonelli A, Marone G, Simon HU, Varricchi G, Galdiero MR (2022) Neutrophil extracellular traps in cancer. Semin Cancer Biol 79:91\u2013104","journal-title":"Semin Cancer Biol"},{"key":"477_CR26","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.4049\/jimmunol.179.5.2936","volume":"179","author":"M Dechant","year":"2007","unstructured":"Dechant M, Beyer T, Schneider-Merck T, Weisner W, Peipp M, van de Winkel JG, Valerius T (2007) Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol 179:2936\u20132943","journal-title":"J Immunol"},{"key":"477_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1040-8428(01)00105-6","volume":"39","author":"M Dechant","year":"2001","unstructured":"Dechant M, Valerius T (2001) IgA antibodies for cancer therapy. Crit Rev Oncol Hematol 39:69\u201377","journal-title":"Crit Rev Oncol Hematol"},{"key":"477_CR28","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.3390\/cancers13174495","volume":"13","author":"U Demkow","year":"2021","unstructured":"Demkow U (2021) Neutrophil extracellular traps (NETs) in cancer invasion, evasion and metastasis. Cancers 13:4495","journal-title":"Cancers"},{"key":"477_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2741\/3237","volume":"14","author":"A Diaz","year":"2009","unstructured":"Diaz A, Suarez E, Blanco R, Lopez A, Montero E (2009) Epidermal growth factor receptor modulates the tumorigenic potential of melanoma. Front Biosci 14:159\u2013166","journal-title":"Front Biosci"},{"key":"477_CR30","doi-asserted-by":"publisher","first-page":"E869","DOI":"10.1073\/pnas.1213653110","volume":"110","author":"B Dreier","year":"2013","unstructured":"Dreier B, Honegger A, Hess C, Nagy-Davidescu G, Mittl PR, Gr\u00fctter MG, Belousova N, Mikheeva G, Krasnykh V, Pl\u00fcckthun A (2013) Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters. Proc Natl Acad Sci USA 110:E869\u2013E877","journal-title":"Proc Natl Acad Sci USA"},{"key":"477_CR31","doi-asserted-by":"publisher","first-page":"73618","DOI":"10.18632\/oncotarget.12037","volume":"7","author":"A El Guerrab","year":"2016","unstructured":"El Guerrab A, Bamdad M, Kwiatkowski F, Bignon YJ, Penault-Llorca F, Aubel C (2016) Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. Oncotarget 7:73618\u201373637","journal-title":"Oncotarget"},{"key":"477_CR32","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1182\/bloodadvances.2021004598","volume":"5","author":"M Evers","year":"2021","unstructured":"Evers M, Rosner T, Dunkel A, Jansen JHM, Baumann N, Ten Broeke T, Nederend M, Eichholz K, Klausz K, Reiding K et al (2021a) The selection of variable regions affects effector mechanisms of IgA antibodies against CD20. Blood Adv 5:3807\u20133820","journal-title":"Blood Adv"},{"key":"477_CR33","doi-asserted-by":"publisher","first-page":"e003163","DOI":"10.1136\/jitc-2021-003163","volume":"9","author":"M Evers","year":"2021","unstructured":"Evers M, Stip M, Keller K, Willemen H, Nederend M, Jansen M, Chan C, Budding K, Nierkens S, Valerius T et al (2021b) Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma. J Immunother Cancer 9:e003163","journal-title":"J Immunother Cancer"},{"key":"477_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1795505","volume":"12","author":"M Evers","year":"2020","unstructured":"Evers M, Ten Broeke T, Jansen JHM, Nederend M, Hamdan F, Reiding KR, Meyer S, Moerer P, Brinkman I, Rosner T et al (2020) Novel chimerized IgA CD20 antibodies: improving neutrophil activation against CD20-positive malignancies. MAbs 12:1795505","journal-title":"MAbs"},{"key":"477_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-1-4939-2272-7_12","volume":"1266","author":"M Fairhead","year":"2015","unstructured":"Fairhead M, Howarth M (2015) Site-specific biotinylation of purified proteins using BirA. Methods Mol Biol 1266:171\u2013184","journal-title":"Methods Mol Biol"},{"key":"477_CR36","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nbt1087","volume":"23","author":"J Fang","year":"2005","unstructured":"Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, Jooss K (2005) Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23:584\u2013590","journal-title":"Nat Biotechnol"},{"key":"477_CR37","doi-asserted-by":"publisher","first-page":"e008342","DOI":"10.1136\/jitc-2023-008342","volume":"12","author":"S Feola","year":"2024","unstructured":"Feola S, Hamdan F, Russo S, Chiaro J, Fusciello M, Feodoroff M, Antignani G, D\u2019Alessio F, Molsa R, Stigzelius V et al (2024) Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcgamma and Fcalpha receptors. J Immunother Cancer 12:e008342","journal-title":"J Immunother Cancer"},{"key":"477_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/imr.13401","volume":"328","author":"S Frampton","year":"2024","unstructured":"Frampton S, Smith R, Ferson L, Gibson J, Hollox EJ, Cragg MS, Strefford JC (2024) Fc gamma receptors: Their evolution, genomic architecture, genetic variation, and impact on human disease. Immunol Rev 328:65\u201397","journal-title":"Immunol Rev"},{"key":"477_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.omtm.2023.02.012","volume":"29","author":"PC Freitag","year":"2023","unstructured":"Freitag PC, Kaulfuss M, Fluhler L, Mietz J, Weiss F, Br\u00fccher D, Kolibius J, Hartmann KP, Smith SN, Munz C et al (2023) Targeted adenovirus-mediated transduction of human T cells in vitro and in vivo. Mol Ther Methods Clin Dev 29:120\u2013132","journal-title":"Mol Ther Methods Clin Dev"},{"key":"477_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200821","volume":"32","author":"PC Freitag","year":"2024","unstructured":"Freitag PC, Kolibius J, Wieboldt R, Weber R, Hartmann KP, van Gogh M, Br\u00fccher D, Laubli H, Pl\u00fcckthun A (2024) DARPin-fused T cell engager for adenovirus-mediated cancer therapy. Mol Ther Oncol 32:200821","journal-title":"Mol Ther Oncol"},{"key":"477_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.761816","volume":"12","author":"AK Gimpel","year":"2021","unstructured":"Gimpel AK, Maccataio A, Unterweger H, Sokolova MV, Schett G, Steffen U (2021) IgA complexes induce neutrophil extracellular trap formation more potently than IgG complexes. Front Immunol 12:761816","journal-title":"Front Immunol"},{"key":"477_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-178","volume":"12","author":"TM Gorges","year":"2012","unstructured":"Gorges TM, Tinhofer I, Drosch M, Rose L, Zollner TM, Krahn T, von Ahsen O (2012) Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 12:178","journal-title":"BMC Cancer"},{"key":"477_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/lc.1999.v133.a94931","volume":"133","author":"TB Haddy","year":"1999","unstructured":"Haddy TB, Rana SR, Castro O (1999) Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 133:15\u201322","journal-title":"J Lab Clin Med"},{"key":"477_CR44","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.omto.2023.01.006","volume":"28","author":"F Hamdan","year":"2023","unstructured":"Hamdan F, Feodoroff M, Russo S, Fusciello M, Feola S, Chiaro J, Antignani G, Greco F, Leusen J, Ylosmaki E et al (2023) Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses. Mol Ther Oncolytics 28:264\u2013276","journal-title":"Mol Ther Oncolytics"},{"key":"477_CR45","doi-asserted-by":"publisher","first-page":"e003000","DOI":"10.1136\/jitc-2021-003000","volume":"9","author":"F Hamdan","year":"2021","unstructured":"Hamdan F, Ylosmaki E, Chiaro J, Giannoula Y, Long M, Fusciello M, Feola S, Martins B, Feodoroff M, Antignani G et al (2021) Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. J Immunother Cancer 9:e003000","journal-title":"J Immunother Cancer"},{"key":"477_CR46","first-page":"42","volume":"4","author":"F Hart","year":"2017","unstructured":"Hart F, Danielczyk A, Goletz S (2017) Human cell line-derived monoclonal IgA antibodies for cancer immunotherapy. Bioeng 4:42","journal-title":"Bioeng"},{"key":"477_CR47","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1016\/j.ymthe.2023.08.018","volume":"31","author":"KP Hartmann","year":"2023","unstructured":"Hartmann KP, van Gogh M, Freitag PC, Kast F, Nagy-Davidescu G, Borsig L, Pl\u00fcckthun A (2023) FAP-retargeted Ad5 enables in vivo gene delivery to stromal cells in the tumor microenvironment. Mol Ther 31:2914\u20132928","journal-title":"Mol Ther"},{"key":"477_CR48","doi-asserted-by":"publisher","first-page":"e0116878","DOI":"10.1371\/journal.pone.0116878","volume":"10","author":"R Haryadi","year":"2015","unstructured":"Haryadi R, Ho S, Kok YJ, Pu HX, Zheng L, Pereira NA, Li B, Bi X, Goh LT, Yang Y et al (2015) Optimization of heavy chain and light chain signal peptides for high level expression of therapeutic antibodies in CHO cells. PLoS ONE 10:e0116878","journal-title":"PLoS ONE"},{"key":"477_CR49","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-021-00571-6","volume":"22","author":"CC Hedrick","year":"2022","unstructured":"Hedrick CC, Malanchi I (2022) Neutrophils in cancer: heterogeneous and multifaceted. Nat Rev Immunol 22:173\u2013187","journal-title":"Nat Rev Immunol"},{"key":"477_CR50","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.7150\/thno.40860","volume":"10","author":"T Hu","year":"2020","unstructured":"Hu T, Liu H, Liang Z, Wang F, Zhou C, Zheng X, Zhang Y, Song Y, Hu J, He X et al (2020) Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis. Theranostics 10:4056\u20134072","journal-title":"Theranostics"},{"key":"477_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202002030","volume":"7","author":"DE Ingber","year":"2020","unstructured":"Ingber DE (2020) Is it time for reviewer 3 to request human organ chip experiments instead of animal validation studies? Adv Sci 7:2002030","journal-title":"Adv Sci"},{"key":"477_CR52","doi-asserted-by":"publisher","first-page":"e0201832","DOI":"10.1371\/journal.pone.0201832","volume":"13","author":"SE Kauder","year":"2018","unstructured":"Kauder SE, Kuo TC, Harrabi O, Chen A, Sangalang E, Doyle L, Rocha SS, Bollini S, Han B, Sim J et al (2018) ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS ONE 13:e0201832","journal-title":"PLoS ONE"},{"key":"477_CR53","doi-asserted-by":"publisher","first-page":"e67106","DOI":"10.7554\/eLife.67106","volume":"10","author":"SJ Kerns","year":"2021","unstructured":"Kerns SJ, Belgur C, Petropolis D, Kanellias M, Barrile R, Sam J, Weinzierl T, Fauti T, Freimoser-Grundschober A, Eckmann J et al (2021) Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. eLife 10:e67106","journal-title":"eLife"},{"key":"477_CR54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1006\/mthe.2001.0516","volume":"5","author":"M Kossila","year":"2002","unstructured":"Kossila M, Jauhiainen S, Laukkanen MO, Lehtolainen P, Jaaskelainen M, Turunen P, Loimas S, Wahlfors J, Yla-Herttuala S (2002) Improvement in adenoviral gene transfer efficiency after preincubation at +37 degrees C in vitro and in vivo. Mol Ther 5:87\u201393","journal-title":"Mol Ther"},{"key":"477_CR55","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2217\/imt-2018-0156","volume":"11","author":"J Kowal","year":"2019","unstructured":"Kowal J, Kornete M, Joyce JA (2019) Re-education of macrophages as a therapeutic strategy in cancer. Immunotherapy 11:677\u2013689","journal-title":"Immunotherapy"},{"key":"477_CR56","doi-asserted-by":"publisher","first-page":"226","DOI":"10.4049\/jimmunol.2300717","volume":"213","author":"S Kumar Bharathkar","year":"2024","unstructured":"Kumar Bharathkar S, Stadtmueller BM (2024) Structural and biochemical requirements for secretory component interactions with dimeric IgA. J Immunol 213:226\u2013234","journal-title":"J Immunol"},{"key":"477_CR57","doi-asserted-by":"publisher","first-page":"e0190125","DOI":"10.1371\/journal.pone.0190125","volume":"12","author":"LM Kuroki","year":"2017","unstructured":"Kuroki LM, Jin X, Dmitriev IP, Kashentseva EA, Powell MA, Mutch DG, Dietz AB, Curiel DT, Hawkins WG, Spitzer D (2017) Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: an opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer. PLoS ONE 12:e0190125","journal-title":"PLoS ONE"},{"key":"477_CR58","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.molimm.2015.09.005","volume":"68","author":"JH Leusen","year":"2015","unstructured":"Leusen JH (2015) IgA as therapeutic antibody. Mol Immunol 68:35\u201339","journal-title":"Mol Immunol"},{"key":"477_CR59","doi-asserted-by":"publisher","first-page":"39356","DOI":"10.18632\/oncotarget.17000","volume":"8","author":"B Li","year":"2017","unstructured":"Li B, Xu L, Tao F, Xie K, Wu Z, Li Y, Li J, Chen K, Pi C, Mendelsohn A et al (2017) Simultaneous exposure to FcgammaR and FcalphaR on monocytes and macrophages enhances antitumor activity in vivo. Oncotarget 8:39356\u201339366","journal-title":"Oncotarget"},{"key":"477_CR60","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.4049\/jimmunol.1003082","volume":"186","author":"S Lohse","year":"2011","unstructured":"Lohse S, Derer S, Beyer T, Klausz K, Peipp M, Leusen JH, van de Winkel JG, Dechant M, Valerius T (2011) Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol 186:3770\u20133778","journal-title":"J Immunol"},{"key":"477_CR61","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/0008-5472.CAN-15-1232","volume":"76","author":"S Lohse","year":"2016","unstructured":"Lohse S, Meyer S, Meulenbroek LA, Jansen JH, Nederend M, Kretschmer A, Klausz K, Moginger U, Derer S, Rosner T et al (2016) An anti-EGFR IgA that displays improved pharmacokinetics and myeloid effector cell engagement in vivo. Cancer Res 76:403\u2013417","journal-title":"Cancer Res"},{"key":"477_CR62","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1080\/19420862.2019.1622940","volume":"11","author":"TN Lombana","year":"2019","unstructured":"Lombana TN, Rajan S, Zorn JA, Mandikian D, Chen EC, Estevez A, Yip V, Bravo DD, Phung W, Farahi F et al (2019) Production, characterization, and in vivo half-life extension of polymeric IgA molecules in mice. MAbs 11:1122\u20131138","journal-title":"MAbs"},{"key":"477_CR63","doi-asserted-by":"publisher","DOI":"10.1177\/2041731414544183","volume":"5","author":"T Magdeldin","year":"2014","unstructured":"Magdeldin T, Lopez-Davila V, Villemant C, Cameron G, Drake R, Cheema U, Loizidou M (2014) The efficacy of cetuximab in a tissue-engineered three-dimensional in vitro model of colorectal cancer. J Tissue Eng 5:2041731414544183","journal-title":"J Tissue Eng"},{"key":"477_CR64","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1016\/j.celrep.2018.05.082","volume":"23","author":"HL Matlung","year":"2018","unstructured":"Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, Franke K, Schornagel K, Verkuijlen P, Janssen H et al (2018) Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Cell Rep 23:3946\u20133959 e3946","journal-title":"Cell Rep"},{"key":"477_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100070","volume":"13","author":"R Maute","year":"2022","unstructured":"Maute R, Xu J, Weissman IL (2022) CD47-SIRPalpha-targeted therapeutics: status and prospects. Immunooncol Technol 13:100070","journal-title":"Immunooncol Technol"},{"key":"477_CR66","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/19420862.2015.1106658","volume":"8","author":"S Meyer","year":"2016","unstructured":"Meyer S, Nederend M, Jansen JH, Reiding KR, Jacobino SR, Meeldijk J, Bovenschen N, Wuhrer M, Valerius T, Ubink R et al (2016) Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting. MAbs 8:87\u201398","journal-title":"MAbs"},{"key":"477_CR67","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34\u201347","journal-title":"Nat Rev Immunol"},{"key":"477_CR68","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3390\/cancers13102461","volume":"13","author":"V Palacio-Castaneda","year":"2021","unstructured":"Palacio-Castaneda V, Dumas S, Albrecht P, Wijgers TJ, Descroix S, Verdurmen WPR (2021) A hybrid in silico and tumor-on-a-chip approach to model targeted protein behavior in 3D microenvironments. Cancers 13:2461","journal-title":"Cancers"},{"key":"477_CR69","doi-asserted-by":"publisher","first-page":"e20220011","DOI":"10.1084\/jem.20220011","volume":"219","author":"DF Quail","year":"2022","unstructured":"Quail DF, Amulic B, Aziz M, Barnes BJ, Eruslanov E, Fridlender ZG, Goodridge HS, Granot Z, Hidalgo A, Huttenlocher A et al (2022) Neutrophil phenotypes and functions in cancer: a consensus statement. J Exp Med 219:e20220011","journal-title":"J Exp Med"},{"key":"477_CR70","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.imlet.2006.04.014","volume":"107","author":"R Reljic","year":"2006","unstructured":"Reljic R (2006) In search of the elusive mouse macrophage Fc-alpha receptor. Immunol Lett 107:80\u201381","journal-title":"Immunol Lett"},{"key":"477_CR71","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.3390\/ijms21103643","volume":"21","author":"A Ricobaraza","year":"2020","unstructured":"Ricobaraza A, Gonzalez-Aparicio M, Mora-Jimenez L, Lumbreras S, Hernandez-Alcoceba R (2020) High-capacity adenoviral vectors: expanding the scope of gene therapy. Int J Mol Sci 21:3643","journal-title":"Int J Mol Sci"},{"key":"477_CR72","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/bjc.1998.700","volume":"78","author":"RC Roovers","year":"1998","unstructured":"Roovers RC, Henderikx P, Helfrich W, van der Linden E, Reurs A, de Bruine AP, Arends JW, de Leij L, Hoogenboom HR (1998) High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting. Br J Cancer 78:1407\u20131416","journal-title":"Br J Cancer"},{"key":"477_CR73","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/19420862.2015.1102812","volume":"8","author":"GJ Rouwendal","year":"2016","unstructured":"Rouwendal GJ, van der Lee MM, Meyer S, Reiding KR, Schouten J, de Roo G, Egging DF, Leusen JH, Boross P, Wuhrer M et al (2016) A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA. MAbs 8:74\u201386","journal-title":"MAbs"},{"key":"477_CR74","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/v16071094","volume":"16","author":"M Salauddin","year":"2024","unstructured":"Salauddin M, Saha S, Hossain MG, Okuda K, Shimada M (2024) Clinical application of adenovirus (AdV): a comprehensive review. Viruses 16:1094","journal-title":"Viruses"},{"key":"477_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31263-x","volume":"13","author":"H Satofuka","year":"2023","unstructured":"Satofuka H, Wang Y, Yamazaki K, Hamamichi S, Fukuhara T, Rafique A, Osako N, Kanazawa I, Endo T, Miyake N et al (2023) Characterization of human anti-EpCAM antibodies for developing an antibody-drug conjugate. Sci Rep 13:4225","journal-title":"Sci Rep"},{"key":"477_CR76","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","volume":"10","author":"KO Saunders","year":"2019","unstructured":"Saunders KO (2019) Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol 10:1296","journal-title":"Front Immunol"},{"key":"477_CR77","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676\u2013682","journal-title":"Nat Methods"},{"key":"477_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02707-6","volume":"9","author":"M Schmid","year":"2018","unstructured":"Schmid M, Ernst P, Honegger A, Suomalainen M, Zimmermann M, Braun L, Stauffer S, Thom C, Dreier B, Eibauer M et al (2018) Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control. Nat Commun 9:450","journal-title":"Nat Commun"},{"key":"477_CR79","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.3390\/ijms23105402","volume":"23","author":"S Shuchat","year":"2022","unstructured":"Shuchat S, Yossifon G, Huleihel M (2022) Perfusion in organ-on-chip models and its applicability to the replication of spermatogenesis in vitro. Int J Mol Sci 23:5402","journal-title":"Int J Mol Sci"},{"key":"477_CR80","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3390\/vaccines9080882","volume":"9","author":"Y Si","year":"2021","unstructured":"Si Y, Zhang Y, Guan JS, Ngo HG, Totoro A, Singh AP, Chen K, Xu Y, Yang ES, Zhou L et al (2021) Anti-CD47 monoclonal antibody-drug conjugate: a targeted therapy to treat triple-negative breast cancers. Vaccines 9:882","journal-title":"Vaccines"},{"key":"477_CR81","doi-asserted-by":"publisher","first-page":"e2017925118","DOI":"10.1073\/pnas.2017925118","volume":"118","author":"SN Smith","year":"2021","unstructured":"Smith SN, Schubert R, Simic B, Br\u00fccher D, Schmid M, Kirk N, Freitag PC, Gradinaru V, Pl\u00fcckthun A (2021) The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody. Proc Natl Acad Sci USA 118:e2017925118","journal-title":"Proc Natl Acad Sci USA"},{"key":"477_CR82","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/intimm\/12.1.19","volume":"12","author":"V Sorensen","year":"2000","unstructured":"Sorensen V, Rasmussen IB, Sundvold V, Michaelsen TE, Sandlie I (2000) Structural requirements for incorporation of J chain into human IgM and IgA. Int Immunol 12:19\u201327","journal-title":"Int Immunol"},{"key":"477_CR83","doi-asserted-by":"publisher","first-page":"e006948","DOI":"10.1136\/jitc-2023-006948","volume":"11","author":"MC Stip","year":"2023","unstructured":"Stip MC, Evers M, Nederend M, Chan C, Reiding KR, Damen MJ, Heck AJR, Koustoulidou S, Ramakers R, Krijger GC et al (2023a) IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models. J Immunother Cancer 11:e006948","journal-title":"J Immunother Cancer"},{"key":"477_CR84","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1007\/s00262-023-03478-4","volume":"72","author":"MC Stip","year":"2023","unstructured":"Stip MC, Jansen JHM, Nederend M, Tsioumpekou M, Evers M, Olofsen PA, Meyer-Wentrup F, Leusen JHW (2023b) Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains. Cancer Immunol Immunother 72:3063\u20133077","journal-title":"Cancer Immunol Immunother"},{"key":"477_CR85","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1089\/hum.2023.221","volume":"35","author":"L Thalmann","year":"2024","unstructured":"Thalmann L, Martin-Gonzalez N, Br\u00fccher D, Pl\u00fcckthun A, de Pablo PJ, Suomalainen M, Greber UF (2024) Gutless helper-dependent and first-generation HAdV5 vectors have similar mechanical properties and common transduction mechanisms. Hum Gene Ther 35:163\u2013176","journal-title":"Hum Gene Ther"},{"key":"477_CR23","unstructured":"The Business Research Company (2023) Monoclonal Antibodies (MAbs) Global Market Report 2023. Retrieved June, 25, 2024, from https:\/\/www.marketresearch.com\/Business-Research-Company-v4006\/Monoclonal-Antibodies-MAbS-Global-33361123\/"},{"key":"477_CR86","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/2326-6066.CIR-19-0144","volume":"8","author":"LW Treffers","year":"2020","unstructured":"Treffers LW, Ten Broeke T, Rosner T, Jansen JHM, van Houdt M, Kahle S, Schornagel K, Verkuijlen P, Prins JM, Franke K et al (2020) IgA-mediated killing of tumor cells by neutrophils is enhanced by CD47-SIRPalpha checkpoint inhibition. Cancer Immunol Res 8:120\u2013130","journal-title":"Cancer Immunol Res"},{"key":"477_CR87","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1182\/blood.V93.12.4387","volume":"93","author":"M van Egmond","year":"1999","unstructured":"van Egmond M, van Vuuren AJ, Morton HC, van Spriel AB, Shen L, Hofhuis FM, Saito T, Mayadas TN, Verbeek JS, van de Winkel JG (1999) Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b\/CD18). Blood 93:4387\u20134394","journal-title":"Blood"},{"key":"477_CR88","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/antib9040070","volume":"9","author":"G van Tetering","year":"2020","unstructured":"van Tetering G, Evers M, Chan C, Stip M, Leusen J (2020) Fc engineering strategies to advance IgA antibodies as therapeutic agents. Antibodies 9:70","journal-title":"Antibodies"},{"key":"477_CR89","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","volume":"7","author":"K Weiskopf","year":"2015","unstructured":"Weiskopf K, Weissman IL (2015) Macrophages are critical effectors of antibody therapies for cancer. MAbs 7:303\u2013310","journal-title":"MAbs"},{"key":"477_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200984","volume":"33","author":"F Weiss","year":"2025","unstructured":"Weiss F, Kolibius J, Freitag PC, Gantenbein F, Kipar A, Pl\u00fcckthun A (2025) Dendritic cell targeting in lymph nodes with modular adapters boosts HAdV5 and HC-HAdV5 tumor vaccination by co-secretion of IL-2v and IL-21. Mol Ther Oncol 33:200984","journal-title":"Mol Ther Oncol"},{"key":"477_CR91","first-page":"5758","volume":"59","author":"J Willuda","year":"1999","unstructured":"Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, Pl\u00fcckthun A (1999) High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 59:5758\u20135767","journal-title":"Cancer Res"},{"key":"477_CR92","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/path.1877","volume":"208","author":"JM Woof","year":"2006","unstructured":"Woof JM, Kerr MA (2006) The function of immunoglobulin A in immunity. J Pathol 208:270\u2013282","journal-title":"J Pathol"},{"key":"477_CR93","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/mi.2011.39","volume":"4","author":"JM Woof","year":"2011","unstructured":"Woof JM, Russell MW (2011) Structure and function relationships in IgA. Mucosal Immunol 4:590\u2013597","journal-title":"Mucosal Immunol"},{"key":"477_CR94","first-page":"849","volume":"21","author":"M Zhang","year":"2024","unstructured":"Zhang M, Qin H, Wu Y, Gao Q (2024) Complex role of neutrophils in the tumor microenvironment: an avenue for novel immunotherapies. Cancer Biol Med 21:849\u2013863","journal-title":"Cancer Biol Med"},{"key":"477_CR95","doi-asserted-by":"publisher","first-page":"1163802","DOI":"10.3389\/fonc.2023.1163802","volume":"13","author":"W Zhong","year":"2023","unstructured":"Zhong W, Wang Q, Shen X, Du J (2023) The emerging role of neutrophil extracellular traps in cancer: from lab to ward. Front Oncol 13:1163802","journal-title":"Front Oncol"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00477-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00477-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00477-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:31:59Z","timestamp":1786516319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00477-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":95,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,12]]}},"alternative-id":["477"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00477-7","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}